The risk of reactivation of resolved hepatitis B virus (HBV) in hepatitis B surface antigen (HBsAg)-negative multiple myeloma patients after daratumumab has not been reported. Among 93 patients with daratumumab treatment, reactivation occurred in 6 patients (6.5%) with one hepatic failure. This is the first report demonstrating a considerable risk of reactivation of resolved HBV after daratumumab.
All Keywords
【저자키워드】 Reactivation, Multiple myeloma, Hepatitis B virus, daratumumab,
【저자키워드】 Reactivation, Multiple myeloma, Hepatitis B virus, daratumumab,